Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering

This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications. Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS. The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature. The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS. The change in the alginate type, revealed characteristics better suited for medical applications by the medium-viscosity alginate. Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications. Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.